{"product_id":"rxrx-five-forces","title":"(RXRX) Recursion Pharmaceuticals, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Recursion Pharmaceuticals, Inc. Porter's Five Forces Analysis helps you assess industry competition, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the report, so you can see the format and content before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CRO and CDMO dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. depends on CROs and CDMOs for discovery, preclinical work, and some clinical development, so specialized vendors can charge premium rates because biotech-grade capacity is scarce and tightly regulated. That raises supplier power, especially for complex assays, GMP manufacturing, and regulated trial support. Still, Recursion can spread work across vendors and shift workstreams, which caps any one supplier’s leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of scientific talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. depends on scarce biologists, chemists, data scientists, automation engineers, and clinical experts, so labor suppliers have real leverage. In 2026, that talent pool is still tight, and top hires can push for higher pay, equity, and flexible terms. Recursion’s AI-driven story helps recruiting, but pharma, biotech, and AI firms all compete for the same people. That keeps supplier power high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on lab materials and instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. depends on niche suppliers for reagents, assays, sequencing tools, robotics, and high-end lab gear, so supplier power stays elevated. In advanced screening and automation, a few vendors can control critical inputs, which can lift costs and slow active pipeline work if shortages hit. That risk matters more in a clinical-stage model, where even small delays can push readouts and raise burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCloud and data infrastructure providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. faces moderate supplier power because its platform needs massive compute, storage, and analytics to run biology and chemistry workflows. Major cloud and software vendors can still shape pricing, service terms, and upgrade timing. The pressure is softened by multi-vendor design and Recursion Pharmaceuticals, Inc. building more of the stack in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh dependence on cloud compute\u003c\/li\u003e\n\u003cli\u003eVendor pricing can move costs\u003c\/li\u003e\n\u003cli\u003eMulti-cloud cuts lock-in risk\u003c\/li\u003e\n\u003cli\u003eInternal engineering weakens suppliers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and academic collaboration partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUniversity and foundation partners can have meaningful leverage because they control early IP, patents, and niche biology know-how that Recursion Pharmaceuticals, Inc. needs for target discovery. Recursion Pharmaceuticals, Inc. also depends on external collaborators for pipeline assets, so a single blocked license can slow a program fast. Long deals, shared milestones, and co-development rights help cap that power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControls early IP and patents.\u003c\/li\u003e\n\u003cli\u003eCan delay key pipeline access.\u003c\/li\u003e\n\u003cli\u003eLong-term deals reduce leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Faces High Supplier Power Across Talent, Labs, and Cloud\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. faces high supplier power because scarce biotech labor, CRO\/CDMO capacity, and niche lab inputs can raise costs and slow work. Cloud vendors also matter: Recursion Pharmaceuticals, Inc. runs compute-heavy AI biology on multi-vendor infrastructure, but switching is still costly. Long-term alliances and split sourcing soften, but do not remove, that leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier group\u003c\/th\u003e\n\u003cth\u003ePower\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalent\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eScarce AI, lab, and clinical hires\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CDMO\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eBiotech-grade capacity is tight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\/vendors\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eCost and uptime can shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses how competition, suppliers, buyers, substitutes, and entry barriers shape Recursion Pharmaceuticals, Inc.’s pricing power and growth outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, clear view of Recursion’s competitive pressures—so strategic risks and opportunities are easy to spot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Recursion Pharmaceuticals, Inc., helping stakeholders verify key claims fast and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma partners as key buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals is still clinical-stage, so its real buyers are pharma partners, not end patients. Big drugmakers can compare many early assets and push for milestone-heavy, risk-sharing deals, which keeps their bargaining power high. Recursion's data platform helps, but larger buyers can still shape pricing, control, and economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement-sensitive healthcare purchasers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. has no approved commercial products yet, so customer power stays limited for now; but if it launches drugs, payers and health systems will shape price and access fast. Rare-disease and oncology drugs can still win premium pricing, often above $100,000 a year, only when the clinical benefit is clear and hard to copy.\u003c\/p\u003e\n\u003cp\u003eIn 2025, U.S. payers kept strong control through formularies, prior authorization, and step edits, which can slow uptake even for strong drugs. Outcomes-based contracts also push Recursion Pharmaceuticals, Inc. to prove real-world value, so bargaining power rises sharply once sales depend on reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrial site and investigator influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical sites, investigators, and patient networks can sway Recursion Pharmaceuticals, Inc. trial speed and data quality, especially in rare diseases where enrollment can take 12 to 24 months. In these programs, a delayed start can burn cash fast; Recursion reported $561 million in cash, cash equivalents, and marketable securities at 2025 year-end, so timing still matters. Broadening site coverage helps reduce this leverage, but execution risk stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient and advocacy group expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Recursion Pharmaceuticals, Inc., patient and advocacy group influence is strongest in rare and severe diseases: about 7,000 rare diseases affect the U.S., and roughly 95% still have no approved therapy, so trial design and endpoints can be shaped by unmet need. This rarely gives direct pricing power, but it can steer development priorities and speed adoption if patients back a program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrongest where options are few\u003c\/li\u003e\n\u003cli\u003eCan shape endpoints and risk tolerance\u003c\/li\u003e\n\u003cli\u003eDrives adoption, not direct pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulators as gatekeepers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulators are not buyers, but they set the bar for approval, labeling, and manufacturing, so they heavily shape Recursion Pharmaceuticals, Inc.’s leverage with future customers. In 2025, the U.S. FDA approved 50 novel drugs, but each still faced steep efficacy, safety, and CMC (chemistry, manufacturing, and controls) demands that can delay or block launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproval risk lifts buyer power.\u003c\/li\u003e\n\u003cli\u003eFDA standards shape market access.\u003c\/li\u003e\n\u003cli\u003eWeak data cuts pricing leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Faces Strong Buyer Power as Access Pressure Stays High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. faces high customer power because its main buyers are pharma partners and, later, payers. In 2025, U.S. payers still used formularies, prior authorization, and step edits, so access and price pressure stay strong. Rare-disease drugs can still earn premium pricing, but only with clear benefit and strong reimbursement support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$561M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovel FDA drugs\u003c\/td\u003e\n\u003ctd\u003e50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare diseases\u003c\/td\u003e\n\u003ctd\u003e7,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eRecursion Pharmaceuticals, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Recursion Pharmaceuticals, Inc. Porter’s Five Forces Analysis you’ll receive after purchase—no edits, no placeholders, and no surprises. It’s the same professionally written, ready-to-use document, formatted for immediate download. What you see here is the final file, so once you buy it, you’ll get instant access to this exact version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded AI drug discovery space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion faces a crowded field of AI-native drug discovery rivals such as Insilico, Exscientia, and Valo, all selling faster target finding and lower R\u0026amp;D cost. That makes rivalry intense because investors and partners can compare platform data, pipeline depth, and clinical milestones side by side. As more capital flows into AI biopharma, the same few big pharma deals and proof points get fought over.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition from established pharma R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge pharma rivals can run in-house discovery and still have the cash to build or buy similar AI tools; many spend over $10 billion a year on R\u0026amp;D. They also bring bigger pipelines and far more late-stage trial experience, which lowers execution risk. Recursion must show its platform lifts hit rates into approved medicines, not just faster target discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRivalry in rare disease and oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals faces heavy rivalry because its pipeline spans rare diseases and oncology, where small patient pools and fast-moving science reward first-in-class or best-in-class wins. GM2 gangliosidosis is ultra-rare at about 1 in 300,000 births, NF2 affects roughly 1 in 25,000 to 33,000 people, and FAP hits about 1 in 8,000 to 10,000, so rivals are chasing the same scarce patients with different mechanisms, delivery methods, and safety profiles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePressure from platform differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech rivalry at Recursion Pharmaceuticals, Inc. is about platform trust, not one asset. The company must prove that its biology, chemistry, automation, and data science engine keeps turning data into clinic-ready drugs; if later trials miss, rivals can win partners and capital fast.\u003c\/p\u003e\n\u003cp\u003eIn Q1 2024, Recursion Pharmaceuticals, Inc. reported $506 million in cash and equivalents, so the market still expects proof that the platform scales. One weak readout can hurt that view. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform must beat peers on data quality.\u003c\/li\u003e\n\u003cli\u003eLater trials decide partner trust.\u003c\/li\u003e\n\u003cli\u003eWeak clinical translation boosts rivals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFunding and milestone race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical-stage biotech rivalry is intense because capital, partners, and market attention move fast. Recursion Pharmaceuticals, Inc. is judged against peers on pipeline breadth and trial readouts; a strong early result can lift valuation, while a miss can weaken bargaining power overnight. With over $500 million in cash reported in recent filings, burn rate still matters. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial wins can reprice biotech stocks fast.\u003c\/li\u003e\n\u003cli\u003eCash runway drives partner leverage.\u003c\/li\u003e\n\u003cli\u003eSetbacks can cut funding options.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion’s Rivalry Is Fierce, and Every Trial Readout Matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because Recursion Pharmaceuticals, Inc. competes with AI drug-discovery peers and large pharma that can fund similar tools. In Q1 2024, Recursion Pharmaceuticals, Inc. reported $506 million in cash and equivalents, so trial wins and partner trust still matter. Scarce rare-disease patient pools make every readout count.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e$506 million cash\u003c\/td\u003e\n\u003ctd\u003eRunway and leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease focus\u003c\/td\u003e\n\u003ctd\u003eFew patients, many rivals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI platform model\u003c\/td\u003e\n\u003ctd\u003eEasy to compare peers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting standard-of-care therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor many Recursion Pharmaceuticals, Inc. targets, approved standard-of-care drugs are the main substitute, and in some diseases patients already have 1-2 reimbursed options. Even if those therapies are weak, doctors may keep using them because they know the dosing, payers cover them, and workflows stay simple. Recursion has to prove clear incremental benefit, not just novelty, to win share from these entrenched options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative modality competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. faces a strong substitute threat because patients and physicians can still choose small molecules, biologics, gene therapies, cell therapies, or even supportive care. As of 2025, Recursion Pharmaceuticals, Inc. has 0 approved products, so rivals with approved therapies can win on speed, convenience, and proven durability. In rare disease and oncology, where multiple modalities often target the same biology, substitution pressure stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWatchful waiting and symptomatic care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWatchful waiting is a real substitute in slow-moving or mixed diseases, because clinicians may choose to monitor first rather than expose patients to a new drug with uncertain benefit-risk. Symptom care can also be enough when disease burden is mild or unstable. Recursion Pharmaceuticals, Inc. still needs clear efficacy and tolerability to beat that inertia, especially with no approved products yet as of 2025\/2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompeting discovery platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompeting discovery platforms are a real substitute threat for Recursion Pharmaceuticals, Inc. because sponsors can shift capital and partnerships to rivals that look more validated, cheaper, or faster. In a market where large pharma keeps spreading bets across AI and high-throughput platforms, Recursion must keep proving preclinical and clinical output to defend collaboration value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners can switch platforms quickly\u003c\/li\u003e\n\u003cli\u003eValidation beats hype in deal-making\u003c\/li\u003e\n\u003cli\u003eSpeed and capital efficiency matter most\u003c\/li\u003e\n\u003cli\u003eOutput is the main defense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging personalized medicine options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmerging personalized medicine can narrow Recursion Pharmaceuticals, Inc.'s addressable market when a drug is built for one biomarker-defined subgroup and beats a broad platform approach in that niche. In oncology and rare disease, biomarker-led therapies already win share because they can improve response and cut trial risk. Recursion needs clear biomarker selection and proof of superiority, or targeted rivals can displace it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiomarker drugs can outcompete broad platforms.\u003c\/li\u003e\n\u003cli\u003eNarrow niches can still take meaningful share.\u003c\/li\u003e\n\u003cli\u003eClinical proof is the key defense.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes companion diagnostics, patient stratification, and strong endpoint data central to Recursion Pharmaceuticals, Inc.'s moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Faces High Substitute Risk Amid Zero Approved Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Recursion Pharmaceuticals, Inc. because approved standard-of-care drugs, supportive care, and watchful waiting can all win when Recursion Pharmaceuticals, Inc. has no approved products as of 2025\/2026. In oncology and rare disease, biomarker-led rivals can also displace broad platforms. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0 approved products\u003c\/td\u003e\n\u003ctd\u003eWeak switching power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025\/2026\u003c\/td\u003e\n\u003ctd\u003eHigh substitute pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capital requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrug discovery is capital heavy: Tufts CSDD estimates the capitalized cost of one approved drug at about $2.6 billion, and the process can take 10 to 15 years. With clinical success rates near 8%, few new entrants can fund the labs, trials, and regulatory work needed to compete. That makes entry hard and helps Recursion if it keeps executing well.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and clinical barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew entrants face steep FDA and global rules, and the gate is narrow: the FDA approved 55 novel drugs in 2023 and 50 in 2024, so most ideas never reach market. Complex trial design, patient recruitment, and safety monitoring add years and heavy cash burn before any revenue. In rare disease and oncology, small patient pools and endpoint demands make compliance even tougher.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and platform scale advantages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion's threat from new entrants is limited by data and platform scale: the Company has spent years building an integrated biology and AI discovery engine, backed by 65+ petabytes of proprietary data and industrial automation. New rivals would need huge datasets, validated lab workflows, and expensive automation before they could match that throughput. Cloud tools lower the start-up cost, but they do not replace the scale gap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLower barriers from AI tooling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLower barriers are real: generative AI and cloud tools let a small team spin up a discovery platform in months, not years. That keeps new entrants alive because they can show early models and a strong story fast, even if wet-lab validation and clinical success still take years and heavy capital.\u003c\/p\u003e\n\u003cp\u003eFor Recursion Pharmaceuticals, Inc., the real moat is not just code; it is data scale, assay quality, and trial execution. So the threat stays moderate, since AI cuts the cost of entry but not the cost of proving a drug works in humans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAI lowers launch cost and speed.\u003c\/li\u003e\n\u003cli\u003eSmall teams can pitch early models.\u003c\/li\u003e\n\u003cli\u003eClinical proof still blocks most entrants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-backed startups and spinouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner-backed spinouts can enter Recursion Pharmaceuticals, Inc.'s rare-disease and oncology lanes fast when they bring licensed IP, star founders, and seed money. The threat is softened by the need for proof-of-concept data, but fresh academic and pharma pipelines keep refilling the field with new rivals. Small teams can still attack the same targets before scale matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed IP lowers entry costs.\u003c\/li\u003e\n\u003cli\u003eExpert founders speed early work.\u003c\/li\u003e\n\u003cli\u003eProof-of-concept still blocks weak entrants.\u003c\/li\u003e\n\u003cli\u003eRare disease and oncology stay crowded.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion's Data Moat Keeps New Entrants in Check\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Recursion Pharmaceuticals, Inc. stays moderate. Drug R\u0026amp;D still needs about $2.6 billion per approved drug, 10-15 years, and about an 8% success rate, so most rivals fail before launch. AI and cloud tools cut startup cost, but they do not replace Recursion Pharmaceuticals, Inc.'s 65+ petabytes of data, lab scale, and trial execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug cost\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel drugs\u003c\/td\u003e\n\u003ctd\u003e55 in 2023; 50 in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecursion Pharmaceuticals, Inc. data\u003c\/td\u003e\n\u003ctd\u003e65+ PB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234979029257,"sku":"rxrx-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rxrx-five-forces.webp?v=1785730670","url":"https:\/\/dcfanalyst.com\/products\/rxrx-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}